The EMA anticipates that the ability to access scientific advice will foster innovation among medical device manufacturers.

In October, the EMA announced that it was looking to improve the efficiency of its approval process for new medicines in the European Union (EU). The stated aim for the agency was to better manage ...

"EMA will no longer post updates and content ... as it decided on the use of vaccines in the European Union. The European Commission and other EU institutions are still active on X.

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

BRUSSELS (AP) — The European Union vows that US tariffs 'will not go unanswered' and will trigger countermeasures. Donald ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...

implied or express statements regarding X4’s expectations related to the EMA’s evaluation of mavorixafor for WHIM syndrome; the potential for MAA approval in the European Union; X4’s plans ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...